Back to Agenda
Cooperation Among Regulators: Impact on Stakeholders
Session Chair(s)
Marie Dray, DIAFellow, MBA
President
International Regulatory Affairs Group LLC, United States
Murray M. Lumpkin, DrMed, MD, MSc
Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative
Bill and Melinda Gates Foundation, United States
In this session, the audience will hear views from the leaders of three of the most influential drug regulatory agencies - The Health Products and Food Branch of Health Canada, the European Medicines Agency and the US FDA - on important issues.
Learning Objective : Discuss current actions in public policy resulting from interagency actions and strategic communications; Determine the impact on organizations of stakeholders.
Speaker(s)
FDA Point of View
Margaret A. Hamburg, MD
NTI | bio Advisory Group, United States
Interim Vice President, Global Biological Policy and Programs; Chair
EMA Point of View
Emer Cooke, MBA, MSc
The European Medicines Agency, Netherlands
Executive Director, Chair, ICMRA
Health Canada Point of View
Paul Glover, MBA
Shared Services Canada, Canada
President
Have an account?